HI-Bio’s $95 Million Series B Financing Round

Goodwin advised Human Immunology Biosciences (HI-Bio) on the round. Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs),...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Palisade Infrastructure’s Acquisition of Washington-Based Assets From Consolidated Communications Inc.

Latham & Watkins Advises Consolidated Communications in Sale of Washington-Based Assets to Palisade. Palisade Infrastructure (Palisade) and Consolidated Communications, Inc. (Consolidated) have entered into an agreement...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Grey Rock’s Investment in Vault

Latham & Watkins represented Vault CCS Holdings in the transaction. Grey Rock Investment Partners (Grey Rock), through its affiliated investment vehicles, has announced an agreement to...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here